{
  "symbol": "INCY",
  "data_type": "company_profile",
  "timestamp": "2025-09-19T14:49:23.071927",
  "data": {
    "address": "1801 Augustine Cut-Off",
    "alias": null,
    "city": "Wilmington",
    "country": "US",
    "currency": "USD",
    "cusip": "45337C102",
    "description": "Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees.  The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.",
    "employeeTotal": 2617,
    "estimateCurrency": "USD",
    "exchange": "NASDAQ NMS - GLOBAL MARKET",
    "finnhubIndustry": "Biotechnology",
    "floatingShare": 190.92,
    "fundamentalFreq": "q",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "insiderOwnership": 1.9993,
    "institutionOwnership": 100.5562,
    "ipo": "1993-12-06",
    "irUrl": "https://investor.incyte.com/",
    "isin": "US45337C1027",
    "lei": "549300Z4WN6JVZ3T4680",
    "logo": "https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/INCY.svg",
    "marketCapCurrency": "USD",
    "marketCapitalization": 16793.748498396228,
    "marketcapUSD": 0,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Incyte Corp",
    "phone": "13024986700",
    "sedol": "2471950",
    "shareOutstanding": 195.28,
    "state": "DELAWARE",
    "ticker": "INCY",
    "usShare": 0,
    "weburl": "https://www.incyte.com/"
  }
}